InflaRx N.V.
NASDAQ:IFRXBiotechnology
-$0.02 today
- Market cap
- $163.58M
- Beta
- 2.44
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.59
Volume 3.05M
Average 1.80M
IFRX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
InflaRx N.V.NASDAQ: IFRX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 68.3% from a year ago
Cash & equivalents stood at €15.01M at the end of Q1 FY2026, down 68.3% from a year earlier and down 6.3% from the prior quarter. Over 3 fiscal years it compounded at -0.5% a year.
Context
- Cash & equivalents amounted to 30.7% of total assets at the end of Q1 FY2026, down 23.7 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -68.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
EUR · from the balance sheet
- Latest · FY2025
- 16.02M EUR
- Year-over-year change
- -12.8%
- 4-year CAGR
- -11.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.02M | -12.8% |
| FY2024 | 2024-12-31 | 18.38M | +43.9% |
| FY2023 | 2023-12-31 | 12.77M | -21.5% |
| FY2022 | 2022-12-31 | 16.27M | -38.0% |
| FY2021 | 2021-12-31 | 26.25M | — |
Cash & Equivalents vs competitors
How IFRX compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -68.3% is the lowest of 9, against a peer median of -30.9%.
- Cash & equivalents amounts to 30.7% of total assets for IFRX, versus a peer median of 43.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $90.42M USD | +48.5% | +4.6% | 88.5% | |
IMAImageneBio Inc | Mar 2026 | $76.05M USD | +106.9% | -16.4% | 55.6% |
| Mar 2026 | $73.68M USD | -30.6% | +7.1% | 30.4% | |
| Mar 2026 | $54.53M USD | -39.0% | +23.0% | 92.6% | |
| Dec 2025 | $38.35M USD | -51.0% | -21.4% | 68.4% | |
KLRSKalaris Therapeutics Inc | Mar 2026 | $34.43M USD | -65.9% | +217.7% | 31.4% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $20.96M USD | -31.1% | -36.1% | 19.8% |
| Mar 2026 | €15.01M EUR | -68.3% | -0.5% | 30.7% | |
| Mar 2026 | $10.01M USD | -3.4% | +2.5% | 12.6% | |
| Peer median (excluding IFRX) | — | -30.9% | +3.5% | 43.5% | |
Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 26.25M | 16.27M | 12.77M | 18.38M | 16.02M |
| Short-term Investments | 57.16M | 65.54M | 0 | 0 | 30.42M |
| Net Receivables | 1.28M | 1.43M | 0 | 0 | 1.43M |
| Inventory | 0 | 0 | 11.37M | 6.9M | 0 |
| Other Current Assets | 0 | 2.55M | 85.06M | 46.03M | 5.75M |
| Total Current Assets | 95.68M | 97.41M | 109.47M | 71.66M | 53.61M |
| Property, Plant & Equipment (Net) | 1.68M | 1.64M | 1.36M | 1.01M | 1.15M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 235.22K | 138.91K | 42.84K | 7.26K | 42.24K |
| Long-term Investments | 27.21M | 2.9M | 9.05M | 3.09M | 237.27K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 336.57K | 308.07K | 283.25K | 247.75K | 151.14K |
| Total Non-current Assets | 29.46M | 4.99M | 10.74M | 4.36M | 1.58M |
| Total Assets | 125.14M | 102.4M | 120.21M | 76.02M | 55.19M |
| Account Payables | 1.69M | 4.99M | 5.1M | 3.41M | 5.4M |
| Short-term Debt | 0 | 0 | 0 | 0 | 256.83K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 8.3M | 6.21M | 0 | 0 | 0 |
| Other Current Liabilities | 1.52M | (1.96M) | 2.89M | 301.54K | 6.16M |
| Total Current Liabilities | 18.76M | 13.03M | 16.84M | 14.17M | 12.98M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 35.02K | 36.88K | 36.88K | 36.88K | 36.86K |
| Total Non-current Liabilities | 1.1M | 1.02M | 782.59K | 435.94K | 677.56K |
| Total Liabilities | 19.86M | 14.05M | 17.63M | 14.6M | 13.65M |
| Common Stock | 5.3M | 5.36M | 7.07M | 7.12M | 8.67M |
| Retained Earnings | (213.98M) | (243.46M) | (286.13M) | (332.19M) | (377.67M) |
| Accumulated OCI | 30.59M | 36.64M | 47.43M | 51.56M | 48.54M |
| Other Stockholders Equity | 3.05M | 7.26M | 1 | 0 | 7.17M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 105.28M | 88.35M | 102.58M | 61.42M | 41.54M |
| Total Debt | 1.43M | 1.36M | 1.12M | 805.09K | 897.53K |
| Net Debt | (24.82M) | (14.91M) | (11.65M) | (17.57M) | (15.12M) |
InflaRx N.V.
NASDAQ:IFRX
Intrinsic Alpha fair value
Locked
Current Price
$1.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.